Daifuku, R.; Grimes, S.; Stackhouse, M.
NUC041, a Prodrug of the DNA Methytransferase Inhibitor 5-aza-2′,2′-Difluorodeoxycytidine (NUC013), Leads to Tumor Regression in a Model of Non-Small Cell Lung Cancer. Pharmaceuticals 2018, 11, 36.
https://doi.org/10.3390/ph11020036
AMA Style
Daifuku R, Grimes S, Stackhouse M.
NUC041, a Prodrug of the DNA Methytransferase Inhibitor 5-aza-2′,2′-Difluorodeoxycytidine (NUC013), Leads to Tumor Regression in a Model of Non-Small Cell Lung Cancer. Pharmaceuticals. 2018; 11(2):36.
https://doi.org/10.3390/ph11020036
Chicago/Turabian Style
Daifuku, Richard, Sheila Grimes, and Murray Stackhouse.
2018. "NUC041, a Prodrug of the DNA Methytransferase Inhibitor 5-aza-2′,2′-Difluorodeoxycytidine (NUC013), Leads to Tumor Regression in a Model of Non-Small Cell Lung Cancer" Pharmaceuticals 11, no. 2: 36.
https://doi.org/10.3390/ph11020036
APA Style
Daifuku, R., Grimes, S., & Stackhouse, M.
(2018). NUC041, a Prodrug of the DNA Methytransferase Inhibitor 5-aza-2′,2′-Difluorodeoxycytidine (NUC013), Leads to Tumor Regression in a Model of Non-Small Cell Lung Cancer. Pharmaceuticals, 11(2), 36.
https://doi.org/10.3390/ph11020036